Maine AG Secures Insulin Price Cap Settlement

Cozen O'Connor
Contact
LinkedIn
Facebook
X
Send
Embed

Cozen O'Connor

  • Maine AG Aaron Frey announced a settlement with Sanofi-Aventis U.S. LLC to resolve allegations that the pharmaceutical company’s deceptive pricing policies resulted in underinsured and uninsured patients to pay higher list prices for insulin.
  • According to the AG’s office, Sanofi will cap out-of-pocket insulin costs at $35 per month for Maine consumers through 2029.  The company also agreed to launch an enrollment message program to notify pharmacists when patients qualify for lower-cost alternatives.
  • The AG’s office urges consumers to ask their pharmacists about their eligibility for low-cost insulin when filling prescriptions.
  • Other AGs have negotiated similar insulin price caps with pharmaceutical companies, including Minnesota AG Keith Ellison and New York AG Letitia James.
Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Cozen O'Connor

Written by:

Cozen O'Connor
Cozen O'Connor
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Cozen O'Connor on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide